Asparaginase Escherichia coli-derived - Medac

Drug Profile

Asparaginase Escherichia coli-derived - Medac

Alternative Names: ASNase; Asparaginase medac™; MC0707; MC1003; rASNase

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medac
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Acute lymphoblastic leukaemia
  • Phase I/II Haematological malignancies

Most Recent Events

  • 16 May 2017 medac plans a phase II trial for Acute lymphoblastic leukaemia in Brazill (NCT03156790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top